Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Candel Therapeutics Inc (CADL)

Candel Therapeutics Inc (CADL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 284,165
  • Shares Outstanding, K 32,476
  • Annual Sales, $ 0 K
  • Annual Income, $ -37,940 K
  • EBIT $ -36 M
  • EBITDA $ -35 M
  • 60-Month Beta -0.95
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 196.84% ( +27.67%)
  • Historical Volatility 252.76%
  • IV Percentile 70%
  • IV Rank 42.76%
  • IV High 452.22% on 12/10/24
  • IV Low 6.03% on 04/15/24
  • Put/Call Vol Ratio 0.24
  • Today's Volume 8,355
  • Volume Avg (30-Day) 5,782
  • Put/Call OI Ratio 0.74
  • Today's Open Interest 40,913
  • Open Int (30-Day) 22,495

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.27
  • Number of Estimates 1
  • High Estimate -0.27
  • Low Estimate -0.27
  • Prior Year -0.38
  • Growth Rate Est. (year over year) +28.95%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.96 +120.68%
on 11/21/24
14.60 -40.07%
on 12/11/24
+4.77 (+119.85%)
since 11/20/24
3-Month
3.79 +131.18%
on 11/15/24
14.60 -40.07%
on 12/11/24
+1.21 (+16.05%)
since 09/20/24
52-Week
1.06 +725.47%
on 12/21/23
14.60 -40.07%
on 12/11/24
+7.63 (+681.25%)
since 12/20/23

Most Recent Stories

More News
Candel Therapeutics Closes $92 Million Public Offering to Advance Cancer Immunotherapy Development

Candel Therapeutics closes public offering, raising approximately $92 million to develop cancer immunotherapy candidates.Quiver AI SummaryCandel Therapeutics, Inc. has successfully closed a public offering...

CADL : 8.75 (-12.15%)
Candel Therapeutics Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

CADL : 8.75 (-12.15%)
Candel Therapeutics Announces $80 Million Public Offering of Common Stock and Pre-Funded Warrants

Candel Therapeutics announces an $80 million public stock offering to fund cancer therapy development and corporate purposes.Quiver AI SummaryCandel Therapeutics, Inc. has announced an underwritten public...

CADL : 8.75 (-12.15%)
Candel Therapeutics Announces Pricing of Public Offering

CADL : 8.75 (-12.15%)
Candel Therapeutics Announces $80 Million Proposed Public Offering

CADL : 8.75 (-12.15%)
Candel Therapeutics Announces Positive Phase 3 Trial Results for CAN-2409 Viral Immunotherapy in Localized Prostate Cancer

Candel's CAN-2409 treatment shows significant disease-free survival benefits for localized prostate cancer in phase 3 trial.Quiver AI SummaryCandel Therapeutics, Inc. announced positive topline results...

CADL : 8.75 (-12.15%)
Candel Therapeutics Stock More Than Doubles After Strong Prostate Cancer Trial Results: Retail Goes Wild

Candel said it plans to initiate talks with the U.S. Food and Drug Administration (FDA) to determine the regulatory pathway for CAN-2409.

CADL : 8.75 (-12.15%)
Candel Therapeutics Announces CAN-2409 Achieved Primary Endpoint in Phase 3 Prostate Cancer Trial, Showing Significantly Improved Disease-Free Survival

CADL : 8.75 (-12.15%)
Candel Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

CADL : 8.75 (-12.15%)
Candel Therapeutics to Present at Jefferies London Healthcare Conference 2024

CADL : 8.75 (-12.15%)

Business Summary

Candel Therapeutics Inc. is a late clinical stage biopharmaceutical company. It involved in developing novel oncolytic viral immunotherapies. The company's product pipeline includes CAN-2409 and CAN-3110. Candel Therapeutics Inc. is based in NEEDHAM, Mass.

See More

Key Turning Points

3rd Resistance Point 11.50
2nd Resistance Point 10.75
1st Resistance Point 9.75
Last Price 8.75
1st Support Level 8.00
2nd Support Level 7.25
3rd Support Level 6.25

See More

52-Week High 14.60
Fibonacci 61.8% 9.43
Last Price 8.75
Fibonacci 50% 7.83
Fibonacci 38.2% 6.23
52-Week Low 1.06

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar